Related Experiment Video

Updated: Oct 8, 2025

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
05:46

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

Published on: May 4, 2021

5.3K

Treatment of patients with Covid-19 with a high dose of ulinastatin

Hai Huang1, Ping-Fang Hu2, Liang-Liang Sun3

  • 1Department of Pulmonary and Critical Care Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China.

Experimental and Therapeutic Medicine
|December 31, 2021
PubMed

Insights

High-dose ulinastatin shows promise in treating COVID-19 patients, improving clinical symptoms and laboratory markers. This COVID-19 treatment was safe and prevented illness deterioration in preliminary findings.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Pharmacology

Background:

  • No specific therapeutic agents are currently available for treating coronavirus disease 2019 (COVID-19).
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to significant respiratory compromise.

Purpose of the Study:

  • To assess the efficacy and safety of high-dose ulinastatin in treating patients with COVID-19.
  • To evaluate the impact of ulinastatin on clinical manifestations, laboratory findings, and chest imaging in COVID-19 patients.

Main Methods:

  • Retrospective analysis of 12 hospitalized patients with confirmed SARS-CoV-2 infection treated with high-dose ulinastatin and standard care.
  • Monitoring of clinical symptoms, laboratory parameters (white blood cell count, lymphocyte percentage, C-reactive protein), and chest imaging.
  • Comparison of outcomes between patients receiving ulinastatin and standard care.

Main Results:

  • Ulinastatin treatment normalized white blood cell counts and lymphocyte percentages in all patients.
  • Hypersensitive C-reactive protein (CRP) levels significantly decreased, returning to normal in 83.3% of patients by day 7.
  • Clinical symptoms improved, peripheral oxygen saturation increased, and 66.7% of patients no longer required oxygen therapy within 7 days.
  • Pulmonary lesions showed absorption, and no patients required intensive care unit admission or mechanical ventilation.
  • Ulinastatin treatment significantly prevented illness deterioration compared to standard care.

Conclusions:

  • High-dose ulinastatin treatment demonstrated a potential beneficial effect in patients with COVID-19.
  • The treatment was found to be safe, with significant improvements in clinical and laboratory markers.
  • Further research is warranted to confirm these preliminary findings and establish ulinastatin as a COVID-19 therapeutic option.

Keywords:
coronavirus disease 2019cytokine storminflammationprotease inhibitorulinastatin

More Related Videos

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

3.7K
Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

7.2K

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
456
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
263
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
273
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
341
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
238
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K